Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial-Reference-Cited by-同舟云学术

Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial

Published:2009-06 Issue:6 Volume:10 Page:549-558
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Grunberg Steven M,Rolski Janusz,Strausz Janos,Aziz Zeba,Lane Stephen,Russo Mark W,Wissel Paul,Guckert Mary,Wright Oliver,Herrstedt Jørn

Publisher

Elsevier BV

Subject

Oncology

Reference27 articles.

1. Chemotherapy-induced nausea and vomiting: prevention, detection, and treatment—how are we doing?;Grunberg;J Support Oncol,2004

2. Serotonin antagonists: a new class of antiemetic agents;Hesketh;J Natl Cancer Inst,1991

3. Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications;Geling;J Clin Oncol,2005

4. Oral ondansetron for the control of delayed emesis after cisplatin: report of a phase II study and a review of completed trials to manage delayed emesis;Kris;Cancer,1992

5. Ondansetron Compared with Granisetron in the Prophylaxis of Cyclophosphamide-lnduced Emesis in Out-Patients: A Multicentre, Double-Blind, Double-Dummy, Randomised, Parallel-Group Study

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis;Cochrane Database of Systematic Reviews;2021-11-16

2. NEPA (netupitant/palonosetron) for the antiemetic prophylaxis of nausea and vomiting induced by chemotherapy (CINV) with Folfirinox and Folfoxiri even during the COVID-19 pandemic: a real-life study;EUR REV MED PHARMACO;2021

3. Olanzapine-Based Triple Regimens Versus Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting Associated with Highly Emetogenic Chemotherapy: A Network Meta-Analysis;The Oncologist;2018-01-12

4. Palliative Care in Obstetrics and Gynecology;Obstetrics & Gynecology;2016-12

5. Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting: A Network Meta-Analysis;Journal of the National Cancer Institute;2016-10-30